by Clinical Neuropsychologist | Wednesday, March 26, 2025 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) selectively affects certain brain regions, yet the mechanisms of selective vulnerability remain poorly understood. The neuromodulatory subcortical system, which includes nuclei exhibiting a range of vulnerability...
by Clinical Neuropsychologist | Wednesday, March 26, 2025 | Dementia
Abstract INTRODUCTION Plasma phosphorylated threonine 181 of tau (pTau181) and amyloid beta (Aβ) are biomarkers for differential diagnosis and preclinical detection of Alzheimer disease (AD). Given differences in AD risk across diverse populations,...
by Clinical Neuropsychologist | Wednesday, March 26, 2025 | Dementia
Abstract INTRODUCTION Distinguishing between molecular changes that precede dementia onset and those resulting from the disease is challenging with cross-sectional studies. METHODS We studied blood DNA methylation (DNAm) differences and incident dementia in two large...
by Clinical Neuropsychologist | Wednesday, March 26, 2025 | Dementia
Alzheimer’s &Dementia, Volume 21, Issue 3, March 2025. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | March 26, 2025 Wiley-Online-Library:...
by Clinical Neuropsychologist | Wednesday, March 26, 2025 | Dementia
Abstract INTRODUCTION We aimed to determine whether cognitively unimpaired (CU) amyloid- beta-positive (Aβ+) individuals display decreased practice effects on serial neuropsychological testing. METHODS We included 209 CU participants from three research centers, 157...
by Clinical Neuropsychologist | Wednesday, March 26, 2025 | Dementia
Abstract INTRODUCTION Disturbances in microvascular flow dynamics are hypothesized to precede the symptomatic phase of Alzheimer’s disease (AD). However, evidence in presymptomatic AD remains elusive, underscoring the need for therapies targeting these early...
